Core Insights - Nuo Cheng Jian Hua's stock increased by 5.09% to 23.96 CNY per share, with a total market capitalization of 42.281 billion CNY as of October 31 [1] Company Overview - Nuo Cheng Jian Hua Pharmaceutical Co., Ltd. is based in Beijing and was established on November 3, 2015, with its IPO on September 21, 2022 [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and R&D services [1] Fund Holdings - Jianxin Fund has a significant position in Nuo Cheng Jian Hua, with its Jianxin High-end Medical Stock A fund holding 147,800 shares, representing 3.39% of the fund's net value [2] - The fund has generated an estimated floating profit of approximately 171,500 CNY today [2] Fund Manager Information - The fund manager of Jianxin High-end Medical Stock A is Pan Longling, who has been in the position for 9 years and 218 days [3] - The fund's total asset size is 162 million CNY, with a best return of 48.64% and a worst return of -31% during the manager's tenure [3]